Skip to main content
. 2020 Feb 6;12(2):137. doi: 10.3390/pharmaceutics12020137

Figure 2.

Figure 2

Dissolution profiles of nilotinib in simulated gastric fluid (SGF) from the A1–A3 formulations (A) and M1–M6 formulations (B).